tbuckley/cabot-search huggingface dataset:
Abstract P2-06-04: Impact of genomic testing on chemotherapy utilization
Authors: L Riley, H Nakijima, K Balinger, D Anderson
Journal: Cancer Research (2012)

Abstract Genomic testing for breast cancer has become a common practice. The two main tests at our institution are Oncotype DX® and MammaPrint®. Each test has unique features and criteria. We sought to compare the practice pattern between these tests and compare them to patients who did not undergo any genomic testing. Methods: This is a retrospective review of all breast cancer patients between May 2008 and August 2011. Data was primarily thorough our tumor registry database. In some cases individual charts were also reviewed. Results: We analyzed 1093 breast cancers in 1064 patients. The average age was 62. The stage at diagnosis was 19% DCIS, 41% stage I, 24% stage II, 11% stage III and 5% stage IV. Of the 1093 cancers, 70 (6%) had an Oncotype test performed, 180 (16%) had a MammaPrint test done, 4 (0.4%) had both test, and 839 (77%) had no genomic test performed. Patients with an Oncotype test were more likely to be stage I than those with a MammaPrint (66% vs 48%). Additionally, patients who had a MammaPrint test more often received chemotherapy when compared to either the Oncotype test or no genomic testing. With a mean follow-up of 1.5 years, there have been 28 recurrences (0 in the Oncotype group, 5 in the MammaPrint group, and 23 in the no genomic testing group). All five of the MammaPrint recurrences were high risk and received adjuvant chemotherapy. Of the 23 recurrences in the no genomic testing group, eight patients were node negative and could have been considered appropriate for genomic testing, 6 of these eight did not have adjuvant chemotherapy. Conclusions: There are distinct practice pattern differences between Oncotype DX® and MammaPrint® utilization. MammaPrint testing was ordered more often in higher staged patients and was associated with an increased use of chemotherapy. This may relate to MammaPrint's previous requirement for fresh tissue that typically occurs before the final nodal status is known. This difference should diminish with the recent availability of MammaPrint on FFPE tissue. All patients who underwent genomic testing and developed a recurrence had been treated with adjuvant chemotherapy. In contrast, patients who did not have a genomic test and experienced a recurrence may have benefited from genomic testing. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-06-04.
B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6
Authors: Shaun W. Jackson, Holly M. Jacobs, Tanvi Arkatkar, Elizabeth M. Dam, Nicole E. Scharping, Nikita S. Kolhatkar, Baidong Hou, Jane H. Buckner, David J. Rawlings
Journal: The Journal of Experimental Medicine (2016)

Dysregulated germinal center (GC) responses are implicated in the pathogenesis of human autoimmune diseases, including systemic lupus erythematosus (SLE). Although both type 1 and type 2 interferons (IFNs) are involved in lupus pathogenesis, their respective impacts on the establishment of autoimmune GCs has not been addressed. In this study, using a chimeric model of B cell-driven autoimmunity, we demonstrate that B cell type 1 IFN receptor signals accelerate, but are not required for, lupus development. In contrast, B cells functioning as antigen-presenting cells initiate CD4(+) T cell activation and IFN-γ production, and strikingly, B cell-intrinsic deletion of the IFN-γ receptor (IFN-γR) abrogates autoimmune GCs, class-switched autoantibodies (auto-Abs), and systemic autoimmunity. Mechanistically, although IFN-γR signals increase B cell T-bet expression, B cell-intrinsic deletion of T-bet exerts an isolated impact on class-switch recombination to pathogenic auto-Ab subclasses without impacting GC development. Rather, in both mouse and human B cells, IFN-γ synergized with B cell receptor, toll-like receptor, and/or CD40 activation signals to promote cell-intrinsic expression of the GC master transcription factor, B cell lymphoma 6 protein. Our combined findings identify a novel B cell-intrinsic mechanism whereby IFN signals promote lupus pathogenesis, implicating this pathway as a potential therapeutic target in SLE.
AB0886 A classification tree for axial spondyloarthritis in individuals with inflammatory back pain from TH
Authors: F. Melchor, I. Pelaez-Ballestas, E. Gutierrez-Peña, A. Lopez, R. Flores-Camacho, E. Navarro-Zarza, R. Burgos-Vargas
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To determine the diagnostic value of inflammatory back pain (IBP) in a classification tree model for axial spondyloarthritis (SpA) in individuals from the community. <h3>Methods</h3> A probabilistic sample of 121 individuals suspected of having IBP (Berlin's criteria) collected during an epidemiological survey of 4,049 individuals assessed for non-traumatic back pain (n=467; COPCORD methodology) and then IBP were included in this study. Their assessment included clinical history, HLA-B27 testing, sacroiliac joint radiographic and magnetic resonance (MRI) imaging studies. Analysis of the data followed the Classification and Regression Tree (CART) methodology. Axial SpA was the dependant variable and 21 demographic and SpA related variables were considered independent. The decision tree was validated in a group of 25 individuals. <h3>Results</h3> Mean age of the group was 41.3 (±11.1) years; 60% were females. The best classification tree model is shown in Figure 1. IBP positive individuals with three or more SpA caharacteristics should be classified as axial SpA. Those with less than three SpA features, but HLA-B27 positive should be also classified as axial SpA. Finally, those with less than three SpA features and HLA-B27 negative, but sacroiliac joint edema on MR should be considered axial SpA as well. This tree erroneously classified 5 individuals (4%). Its sensitivity and specificity were 84.62% and 96.30% and its +LR was 73.33%. A second classification tree (based on Rudawaleit's one) disclosed the following partioning decisions: Regardless SpA features, individuals with IBP and either sacroiliac joint edema on MR or HLA-B27 should be considered as axial SpA. Classification errors were 6 (5%) and their sensitivity, specificity, andn +LR were 92.3%, 95.37%, andy 19.9%, respectively. <h3>Conclusions</h3> The results of our study suggest that in community studies, the classification of individuals as axial SpA should follow the route IBP, SpA features, and then HLA-B27 followed by MR if necessary Funding: CONACYT-Salud 2007-C01-69439. Abbott Laboratories de México: MRI funding <h3>Disclosure of Interest</h3> None Declared
Results of a Planned Attack on Carcinoma of the Vulva
Authors: S. Way
Journal: BMJ (1954)

COLLAGEN DISEASE TREATED WITH CORTICOIDS MEDIC&LNRNALEach patient has been maintained in reasonably good health by the continued administration of cortisone.I am grateful to Dr. Ernest Bulmer for permission to publish Cases 1 and 2, and to Dr. A. G
COMBINATION OF CLINICAL SYNTAX SCORE AND NEUTROPHIL TO PLATELET RATIO COULD IDENTIFY PATIENTS WITH ACUTE CORONARY SYNDROME AT HIGHER RISK OF POOR OUTCOME
Authors: Takumi Kondo, Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Masashi Ishimi, Hideyuki Hakui, Tatsuhisa Ozaki, Yoshihiro Sato, Masahiro Seo, Iyo Ikeda, Eiji Fukuhara, Masatake Fukunami
Journal: Journal of the American College of Cardiology (2016)
PERFORMANCE OF THE RIGHT VENTRICULAR FAILURE RISK SCORE IN PATIENTS SUPPORTED WITH A LEFT VENTRICULAR ASSIST DEVICE
Authors: Sangjin Lee, Lina Vargas, Santosh Rao, Carmel Halley, Zhiyuan Sun, Maria Mountis, Gonzalo Gonzalez-Stawinski, Nicholas Smedira, Kiyotaka Fukamachi, Randall Starling
Journal: Journal of the American College of Cardiology (2012)
SHOULD WE REFINE THE DEFINITION OF VALVULAR ATRIAL FIBRILLATION BASED ON ECHOCARDIOGRAPHIC CRITERIA? A SINGLE CENTER COHORT STUDY WITH MID-TERM FOLLOW-UP
Authors: Sylvie Lang, Laurie Soulat-Dufour, Ciham El Asri, Louise Boyer-Chatenet, Stephane Ederhy, Clelie Van der Vynckt, Nabila Haddour, Saroumadi Adavane, Franck Boccara, Ariel Cohen
Journal: Journal of the American College of Cardiology (2016)
PAPEL DE LA USE-PAAF EN EL DIAGNÓSTICO DE LESIONES MEDIASTÍNICAS
Authors: A Matas Cobos, C González Artacho, M Ojeda Hinojosa, V Martos Ruiz, E Redondo Cerezo, J Martínez Cara, D Sánchez Capilla, M López De Hierro, J De Teresa Galván
Journal: Endoscopy (2011)

Introducción: La mediastinoscopia se considera el patrón oro para el diagnóstico de lesiones mediastínicas. Se realiza en un quirófano y bajo anestesia general. Presenta un 16% de morbilidad y un 0,08% de mortalidad. La USE-PAAF es una técnica bien tolerada y segura para el diagnóstico de lesiones mediastínicas sin necesidad de anestesia general. En comparación a la mediastinoscopia presenta menor índice de complicaciones. Según los últimos estudios publicados la mortalidad se encuentra en torno a 0,06%, siendo de un 0,02 a un 2,2% las complicaciones presentadas.
Preoperative routine evaluation of bilateral adrenal glands by endoscopic ultrasound and fine-needle aspiration in patients with potentially resectable lung cancer
Authors: S. Uemura, I. Yasuda, T. Kato, S. Doi, J. Kawaguchi, T. Yamauchi, Y. Kaneko, R. Ohnishi, T. Suzuki, S. Yasuda, K. Sano, H. Moriwaki
Journal: Endoscopy (2013)

<b>Background and study aims:</b> The aim of the current study was to assess the detection rate of the right adrenal gland and the diagnostic ability of endoscopic ultrasound (EUS) and fine-needle aspiration (FNA) for the diagnosis of adrenal metastasis in potentially resectable lung cancer. <b>Patients and methods: </b>This retrospective cohort study included a consecutive series of 150 patients undergoing EUS/EUS – FNA for staging of lung cancer. The detection rate of the right adrenal gland by EUS and the diagnostic accuracies of computed tomography (CT), positron emission tomography-CT (PET-CT), and EUS/EUS – FNA for the diagnosis of adrenal metastasis were evaluated. <b>Results:</b> The right adrenal gland was visualized by EUS in 131 patients (87.3 %); the left adrenal gland was visualized in all patients. Findings suggestive of metastasis in either one of the adrenal glands or in both were observed in 6 patients (4.0 %) by CT, in 5 patients (3.3 %) by PET-CT, and in 11 patients (7.3 %) by EUS. EUS – FNA was performed simultaneously in the 11 patients, and in 4 patients the diagnosis of metastasis was established. The accuracy for the diagnosis of adrenal metastasis was 100 % for EUS/EUS – FNA, 96.0 % for CT, and 97.0 % for PET-CT (<i>P</i> = 0.1146). <b>Conclusions:</b> As well as the left adrenal gland, the right adrenal gland was also usually visible by EUS. EUS/EUS – FNA provided an accurate diagnosis of adrenal metastasis, although the prevalence of adrenal metastasis was relatively low in these patients with potentially resectable lung cancer.
Sentinel Node Mapping in Patients with Malignant Melanoma Using Melanoma Tc-99m Colloidal Rhenium Sulfide
Authors: Mayo Weiss, Christian Kunte, Rupert Alfons Schmid, Birger Konz, Stefan Dresel, Klaus Hahn
Journal: Clinical Nuclear Medicine (2003)

Purpose The aim of the study was to localize the sentinel lymph node using lymphoscintigraphy aided by Tc-99m colloidal rhenium sulfide. Materials and Methods Thirty consecutive patients with histologically proved melanoma, but no clinical evidence of metastases, were examined before operation by injecting 20 to 40 MBq (0.5 to 1.1 mCi) Tc-99m colloidal rhenium sulfide with a mean particle size of 100 nm (range, 50 to 200 nm) intradermally around the lesion. Lymphoscintigraphy was performed immediately after injection. In addition, blue dye was injected before operation. A hand-held gamma probe guided the sentinel node biopsy. Results Lymphoscintigraphy revealed hot spots in all patients. During surgery, the sentinel node was identified in all 30 patients. The number of sentinel nodes per patient ranged from 1 to 4 (mean, 1.9). Histologic examination confirmed the metastatic involvement of the sentinel lymph node in 11 of 30 patients. The sentinel lymph node–positive rate was 22.4%, which was comparable to findings using Tc-99m–labeled nanocolloids. Conclusion The findings indicate that Tc-99m–bound colloidal rhenium sulfide is suitable for sentinel node mapping.
Interventional Radiology in the Chest and Abdomen
Authors: Peter R. Mueller, Eric van Sonnenberg
Journal: New England Journal of Medicine (1990)

OVER the past 10 years, interventional radiology has become an essential subspecialty of general radiology. It has evolved from providing purely diagnostic information (e.g., antegrade pyelography and percutaneous transhepatic cholangiography) to offering palliative therapy (e.g., percutaneous nephrostomy and percutaneous biliary drainage). These percutaneous radiologically guided procedures are effective alternatives in the treatment of a variety of abdominal and thoracic disorders.Historically, many of the early developments in percutaneous techniques were first applied to the vascular system; Dotter,1 Grüntzig,2 Amplatz,3 Seldinger,4 Baum,5 and Ring6 and their colleagues developed guidewires, catheters, and balloons that could be used to diagnose and treat various . . .
IMPACT OF MAJOR BLEEDING AS DEFINED BY NATIONAL CARDIOVASCULAR DATA REGISTRY ACROSS DIFFERENT BASELINE HEMOGLOBIN LEVELS IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Authors: Amgad G. Mentias, Amr F. Barakat, Mohammad Raza, Elizabeth Hill, Mehdi Shishehbor, Leslie Cho, A. Lincoff, Stephen Ellis, Samir Kapadia
Journal: Journal of the American College of Cardiology (2016)
COMBINED NT-PROBNP AND ST2 MEASUREMENT HAS POWERFUL PROGNOSTIC VALUE IN CARDIOGENIC SHOCK CAUSED BY ACUTE CORONARY SYNDROME
Authors: Heli Tolppanen, Mercedes Rivas Lasarte, Johan Lassus, Alessandro Sionis Green, Veli-Pekka Harjola, Alexandre Mebazaa
Journal: Journal of the American College of Cardiology (2016)
Abstract 4178: N-cadherin haploinsufficiency prolongs survival in a genetically engineered mouse model of pancreatic cancer
Authors: Yanrong Su, Jifen Li, Leeanne Griffith, Glenn Radice
Journal: Cancer Research (2010)

Abstract Cadherin switching (E-cadherin to N-cadherin) associated with epithelial-mesenchymal transition is implicated in the transition from benign tumors to invasive, malignant cancer and the subsequent metastatic dissemination of tumor cells. Although N-cadherin upregulation has been observed in many cancer types including pancreatic ductal adenocarcinoma (PDA), the importance of this cell adhesion receptor in disease progression is not well understood. The concomitant expression of oncogenic KrasG12D and a mutant Trp53R172H allele in the developing murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genetic changes required for tumor progression. Here we determine the consequences of genetically blocking the switch to N-cadherin in a mouse model of PDA. Two independent N-cadherin mutant alleles were used in these genetic studies. Remarkably, pancreatic cancer mice heterozygous for N-cadherin (n=17) survived 25% longer (177 vs. 142 days, p &amp;lt;0.05) than N-cadherin wild-type mice (n=16). The survival benefit may be due, at least in part, to increased cell death in the N-cadherin heterozygous tumors. Furthermore, cell death was also increased in tumor cell lines isolated from the N-cadherin heterozygous tumors demonstrating a cell-autonomous apoptotic phenotype. Interestingly, tumors lacking N-cadherin (i.e. null) did not show a survival benefit possibly due to compensation by an alternative metastatic promoting molecule(s). In conclusion, our genetic studies indicate that interfering with N-cadherin-mediated adhesion/signaling delays tumor progression, at least in part, by promoting tumor cell death, thus providing further evidence that N-cadherin antagonists may have therapeutic potential for the treatment of pancreatic cancer in humans. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4178.
Gene Transcripts in the Tumor Suppressor Region of Chromosome 3 (3p21).
Authors: W. Al Sarakbi, W. Sasi, W. Jiang, T. Roberts, R. Newbold, K. Mokbel
Journal: Cancer Research (2009)

Abstract Background:There is increasing evidence that the short arm of chromosome 3 has a tumour suppressor region that has been associated with permanent growth arrest of tumour cells. We have identified 9 closely related genes in this region (CCDC12, KLH9, KLH18, MYL3, NBEAL2, PTPN23, SCAP, SETD2, and TESSP2) located which could be possible candidates for tumour suppressor genes (TSG).Our objective was to determine, using quantitative PCR, whether the mRNA expression levels of these genes were consistent with a tumour suppressive function in human breast cancer.Methods:A total of 153 samples were analysed. The levels of transcription of all 9 genes were determined using quantitative PCR and normalized against (CK19).Transcript levels within breast cancer specimens were compared with non-cancerous breast tissue and analyzed against conventional pathological parameters and clinical outcome over a 10 year follow-up period.Results:Quantification of CCDC12, KLH9, KLH18, MYL3, NBEAL2, PTPN23, and SCAP mRNA expression after CK19 normalisation showed no statistically significant difference between malignant and normal breast tissue (p=0.23, 0.46, 0.3, 0.141, 0.8, 0.696, and 0.11 respectively). The mRNA expression of TESSP2 was higher in normal samples compared with malignant lesions (347 vs. 35, p=0.0061) but showed no significant associations with clinical outcome.The levels of SETD2 mRNA were significantly lower in malignant samples (406 vs. 17, p=0.0345) and decreased with increasing tumour stage. SETD2 expression levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died from breast cancer when compared to those who were disease free for &amp;gt; 10 years (p=0.041).Conclusion:These findings are consistent with a possible tumour suppressor function of SETD2 in human breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6139.
Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer.
Authors: CS Hall, BG Debeb, W Xu, NT Ueno, JM Reuben, F Robertson, A Lucci, TA Buchholz, GN Hortobagyi, M Cristofanilli, WA Woodward
Journal: Cancer Research (2009)

Abstract Abstract #1051 Wnt-1-induced secreted protein 3 (WISP3) is a member of the CCN family of proteins, which also includes connective tissue growth factor (CTGF), Cy61, Nov, WISP1, and WISP2. WISP3, as well as the other CCN family members, plays important roles in cellular processes such as proliferation, migration, and survival. WISP3 was originally isolated as Lost in Inflammatory Breast Cancer (LIBC) based on its expression in only 20% of human IBC tumors. Lack of WISP3 expression has also been reported in the IBC-derived cell line SUM-149. In SUM149 cells WISP3 has been reported to function as a tumor suppressor capable of decreasing proliferation and maintaining an epithelial phenotype. Here we examine the expression of WISP3 in a novel aggressive IBC cell line with epithelial-mesenchymal transition (EMT) morphology and abundant WISP3 expression. MDA-IBC-1 cells were isolated from the pleural fluid of a patient with ER+, PR-, HER2/neu- IBC. In 2-dimensional (2D) adherent culture, MDA-IBC-1 cells exhibit fibroblast-like EMT morphology and express EMT-associated proteins such as N-cadherin, vimentin, and fibronectin. Correspondingly, E-cadherin protein expression is absent in 2D cultures. MDA-IBC-1 cells derived from 2D cultures form mammospheres when cultured in 3-dimensional (3D) progenitor promoting conditions. Interestingly, the expression of EMT molecular markers is absent in 3D progenitor promoting mammosphere culture. MDA-IBC-1 cells exhibit robust WISP3 protein expression in both 2D and 3D culture (1.8-fold higher in 3D). In addition, MDA-IBC-1 cells secrete WISP3 as indicated by the presence of WISP3 protein in MDA-IBC-1 derived conditioned media. WISP3 binding is reported to decrease insulin-like growth factor-1 (IGF-1) activation of the IGF1R signaling cascade in SUM-149 cells. IGFR1 protein is present in 2D and 3D cultured MDA-IBC-1 cells. IGF-1 protein overlay assays using conditioned media demonstrate a WISP3:IGF-1 interaction, suggesting functional folding. Serum-free MDA-IBC-1 conditioned media did not increase basal SUM149 proliferation and it inhibited IGF-1 stimulated proliferation to serum-free (basal) levels (p≤0.05). In addition, culturing SUM-149 cells in conditioned media obtained from IBC-1 cells significantly alters SUM-149 to a completely fibroblastic morphology. These data demonstrate that MDA-IBC-1 cells represent an IBC cell line with novel expression and regulation of WISP3. MDA-IBC-1 cells may better represent the cohort of IBC patients whose tumors express WISP3. This data suggest WISP3 may not function as a tumor suppressor in all IBC patients. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1051.
Abstract 3647: Integrin β5 as a new target in ovarian cancer treatment
Authors: Chifumi Ohyagi, Kenjiro Sawada, Yasuto Kinose, Yasuhiko Tomita, Ken-ichirou Morishige, Shoji Kamiura, Tadashi Kimura
Journal: Cancer Research (2012)

Abstract [Background] Ovarian cancer is a highly metastatic characterized by widespread peritoneal dissemination andascites, and is the leading cause of death from gynecological malignancies. Previously, we identified integrin β5 as a key molecule for peritoneal dissemination. In this study, we aimed to determine the predictivevalue of integrin β5 in Japanese ovarian cancer patients.[Methods] Ovarian carcinoma samples were collected from 148 patients who were treated at Osaka Medical Center for Cancer and Cardiovascular Disease (Osaka, Japan) between 2000 and 2005 and were subject to the tissue microarray (TMA) slides. Satisfactory spots and clinical data were obtained from 114patients. The slides were stained with an antibody against human integrin β5 and each sample was scored based on the percentage of positive cells (0, α10%;1, 10-25%; 2, 25-50%; 3, Δ50%) and the intensity of the staining (0, none; 1, very weak; 2, weak; 3, strong). Overexpression was defined if the total scoreof density and intensity is Δ5. “Low” expression was defined if the total score of density and intensity scores was α4. Survivalestimates were computed using the Kaplan-Meier method, and comparisons between groups were analyzed using the log-rank test.[Results] Of 114 patients, 33(29.8%) had integrin β5 overexpression, including 6 of 30 serous (20.0%), 1 of 12 mucinous (8.3%), 1of 13 endometrioid (7.7%), 13 of 17 clear cell (75.6%), 7 of 26 low potential malignant (26.9%) and 5 of 18 others (27.8%) ovarian carcinomas. Among patients with advanced stages (stage lll/lV), those who had integrin β5 overexpression showed significantly worse overall survival than those who had low expression (11.2 months vs 40.0months, P=0.05).[Conclusion] Integrin β5 overexpression was seen in most of clear cell carcinoma, which is extremely resistantto the current chemotherapies. Besides, in advanced ovarian cancer patients, integrin β5 was an independent prognostic maker. These datasuggested that targeting this integrin could be a promising treatment option, at least, for a subset of ovarian cancer such as clear cell carcinoma and needs to be explored for future clinical application. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3647. doi:1538-7445.AM2012-3647